Skip to main content

Yellow III Trial Finds That Lipid Lowering With a PCSK9 Inhibitor Could Benefit Heart Patients on Statin Therapy


A study offers evidence that aggressive lipid lowering with a PCSK9 inhibitor, along with a statin, can significantly reduce that threat and potentially help doctors identify patients who would benefit most from treatment to change their coronary plaque morphology and composition.

Learn More